Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMV-564 |
Synonyms | |
Therapy Description |
AMV-564 is a tandem diabody that targets both CD33 and CD3, which may result in increased T-cell activation and death of CD33-expressing tumor cells (PMID: 27189165, PMID: 28157217). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMV-564 | AMV564|AMV 564|T652 | CD3 Antibody 99 CD33 Antibody 13 | AMV-564 is a tandem diabody that targets both CD33 and CD3, which may result in increased T-cell activation and death of CD33-expressing tumor cells (PMID: 27189165, PMID: 28157217). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03516591 | Phase I | AMV-564 | A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes | Completed | USA | 0 |
NCT04128423 | Phase I | AMV-564 | Study of AMV564 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT03144245 | Phase I | AMV-564 | Study of AMV564 in Patients With AML | Completed | USA | 0 |